A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Patients With Poor Prognosis Hepatocellular Carcinoma

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.